Kidney Cancer

1. Front Matter

   Pages i-ix

   PDF

2. Introduction

   1. Front Matter

      Pages 1-1

      PDF

   2. Molecular Genetics of Kidney Cancer

      • Michael Zimmer, Othon Iliopoulos

      Pages 3-26

   3. Mechanisms of Immune Dysfunction in Renal Cell Carcinoma

      • Ithaar H. Derweesh, Charles S. Tannenbaum, Patricia A. Rayman, James H. Finke

      Pages 29-51

   4. New Algorithms for the Staging of Kidney Cancer

      • D. Leibovici, A. Sella, I. Y. Siegel, A. Zisman

      Pages 53-68

   5. Basic Biology and Clinical Behavior of Renal Cell Carcinoma

      • Ken–ryu Han, Allan J. Pantuck, Arie S. Belldegrun

      Pages 69-89

3. Kidney Cancer: Surgical Approaches

   1. Front Matter

      Pages 91-91

      PDF

   2. Nephron-Sparing Surgery for Renal Cell Carcinoma

      • Ithaar H. Derweesh, Andrew C. Novick

      Pages 93-97

   3. Laparoscopic Radical Nephrectomy and Minimally Invasive Surgery for Kidney Cancer

      • Nicolette K. Janzen, Kent T. Perry, Peter G. Schulam

      Pages 99-117

   4. Role of Nephrectomy in Metastatic Kidney Cancer

      • Paul M. Yonover, Sameer K. SharmA, Robert C. Flanigan

      Pages 119-135

4. Metastatic Renal Cell Carcinoma: Current and Future Approaches

   1. Front Matter

      Pages 137-137

      PDF

   2. Prognostic Factors for Metastatic Kidney Cancer

      • Beverly J. Drucker, Madhu Mazumdar, Robert J. Motzer

      Pages 139-153

   3. Interleukin-2 Based Therapy for Kidney Cancer

      • Janice P. Dutcher

      Pages 155-172

   4. The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer

      • Christopher M. George, Walter M. Stadler

      Pages 173-182

   5. Cell, Gene and Vaccine Based Strategies in Kidney Cancer

      • Barbara J. Gitlitz, A. Robert Figlin

      Pages 183-198

   6. Monoclonal Antibody Therapy of Kidney Cancer

      • Egbert Oosterwijk, Adrienne Brouwers, OTTO C. Boerman, Steven M. Larson, Lloyd J. Old, Peter Mulders et al.

      Pages 199-212

   7. Allogeneic Hematopoetic Stem Cell Transplantation for Cytokine Refractory Renal Cell Carcinoma

      • Darrel Drachenberg, Richard W. CHilds

      Pages 213-226

   8. Novel Therapies for Renal Cell Carcinoma

      • Samira Syed, Anthony W. Tolcher

      Pages 227-238

5. Back Matter

   Pages 239-246

   PDF

Kidney cancer is a heterogenous disease. This book covers:

-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer.

Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.

• Staging
• cancer
• carcinoma
• cell
• genetics
• kidney
• minimally invasive surgery
• molecular genetics
• prevention
• renal cell carcinoma
• stem cell
• stem cell transplantation
• surgery
• transplantation
• surgical oncology

"This text provides a comprehensive overview of kidney cancer. Investigative leaders in the field discuss the genetic, biologic and clinical manifestations of the disease. Modern therapy is reviewed with commentary on future alternatives and novel compounds."
(Steven T. Rosen, M.D., Series Editor)

• University of California, Los Angeles, USA

  Robert A. Figlin

Robert A. Figlin, Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.

Policies and ethics